Clinical factors associated with discontinuation of ts/bDMARDs in rheumatic patients from the BIOBADASER III registry

Clinical factors associated with discontinuation of ts/bDMARDs in rheumatic patients from the BIOBADASER III registry

Abstract Biologic and targeted synthetic disease-modifying antirheumatic drugs (ts/bDMARDs) play a pivotal role in the treatment of rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS). Persistence of therapy provides an index of a drug’s overall effectiveness. The o...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: A. Prior-Español, C. Sánchez-Piedra, J. Campos, F. J. Manero, C. Pérez-García, C. Bohórquez, N. Busquets-Pérez, J. M. Blanco-Madrigal, C. Díaz-Torne, F. Sánchez-Alonso, L. Mateo, S. Holgado-Pérez
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
Medicine
R
Science
Q
Acceso en línea:https://doaj.org/article/6b574cc67451470a97090fb433d3f615
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/6b574cc67451470a97090fb433d3f615

Ejemplares similares